Skip to content
Med Pharma News

Med Pharma News

Your Daily Dose of Pharma News

  • About Med Pharma News
  • Contact Us
  • News
  • Privacy Policy
  • Terms and Conditions
Roundup settlement infographic: Bayer $7.25 billion deal and payout range
  • Industry Insights
32 minutes ago

Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out

A Missouri judge approved Bayer’s Roundup settlement of up to $7.25 billion over 21 years. Who qualifies, payout tiers of $10,000 to $165,000, and what comes next.

  • Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul
  • MAHA ELEVATE Model: CMS Awards $47M to 15 Groups to Test Lifestyle Medicine in Medicare
  • AI Drug Discovery Timelines: Big Pharma Says Early Research Now Runs Up to Twice as Fast
Novo Nordisk layoffs infographic: 215 jobs cut at Plainsboro US headquarters
  • Industry Insights
13 hours ago

Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul

Novo Nordisk will cut 215 jobs at its Plainsboro, New Jersey headquarters in February 2027, taking 2026 US HQ cuts to 323 as it redesigns its sales force.

  • Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out
  • MAHA ELEVATE Model: CMS Awards $47M to 15 Groups to Test Lifestyle Medicine in Medicare
  • AI Drug Discovery Timelines: Big Pharma Says Early Research Now Runs Up to Twice as Fast
MAHA ELEVATE model infographic: $47 million to 15 organisations from 450 applications
  • Industry Insights
17 hours ago

MAHA ELEVATE Model: CMS Awards $47M to 15 Groups to Test Lifestyle Medicine in Medicare

HHS and CMS awarded $47 million to 15 organisations under the MAHA ELEVATE model to test nutrition and exercise programmes for chronic disease in Original Medicare.

  • Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out
  • Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul
  • AI Drug Discovery Timelines: Big Pharma Says Early Research Now Runs Up to Twice as Fast
Rasonque EU approval infographic showing daraxonrasib survival of 13.2 months versus 6.7 months on chemotherapy
  • Pharmaceuticals
18 hours ago

Rasonque EU Approval: Daraxonrasib Becomes Europe’s First RAS Pill for Pancreatic Cancer

The European Commission has approved Revolution Medicines’ Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, with or without a RAS mutation. Here is what the label covers and when patients may get it.

  • Barzolvolimab Atopic Dermatitis Trial Fails: Celldex Drops Eczema to Focus on Hives
  • Savara Molgramostim FDA Decision Delayed: No New Date for First aPAP Drug
  • Xanamem Alzheimer’s Trial Misses Main Goal, Actinogen Shares Plunge Over 80%
  • Industry Insights

Teva Price-Fixing Settlement: 45 States Strike Deal in Generic Drug Collusion Case

Megan Wood 32 minutes ago
  • Industry Insights

Nutrigenomics Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 32 minutes ago
Roundup settlement infographic: Bayer $7.25 billion deal and payout range
  • Industry Insights

Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out

Megan Wood32 minutes ago09 mins

A Missouri judge approved Bayer’s Roundup settlement of up to $7.25 billion over 21 years. Who qualifies, payout tiers of $10,000 to $165,000, and what comes next.

Read More
Novo Nordisk layoffs infographic: 215 jobs cut at Plainsboro US headquarters
  • Industry Insights

Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul

Megan Wood13 hours ago09 mins

Novo Nordisk will cut 215 jobs at its Plainsboro, New Jersey headquarters in February 2027, taking 2026 US HQ cuts to 323 as it redesigns its sales force.

Read More
MAHA ELEVATE model infographic: $47 million to 15 organisations from 450 applications
  • Industry Insights

MAHA ELEVATE Model: CMS Awards $47M to 15 Groups to Test Lifestyle Medicine in Medicare

Megan Wood17 hours ago09 mins

HHS and CMS awarded $47 million to 15 organisations under the MAHA ELEVATE model to test nutrition and exercise programmes for chronic disease in Original Medicare.

Read More
Rasonque EU approval infographic showing daraxonrasib survival of 13.2 months versus 6.7 months on chemotherapy
  • Pharmaceuticals

Rasonque EU Approval: Daraxonrasib Becomes Europe’s First RAS Pill for Pancreatic Cancer

Megan Wood18 hours ago010 mins

The European Commission has approved Revolution Medicines’ Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, with or without a RAS mutation. Here is what the label covers and when patients may get it.

Read More
Barzolvolimab atopic dermatitis Phase 2 results infographic
  • Pharmaceuticals

Barzolvolimab Atopic Dermatitis Trial Fails: Celldex Drops Eczema to Focus on Hives

Megan Wood20 hours ago20 hours ago09 mins

Celldex is ending barzolvolimab development in atopic dermatitis after a 131-patient Phase 2 missed its itch endpoint at both doses. The data, the biology behind the miss and what remains in the pipeline.

Read More
Savara molgramostim FDA delay infographic for autoimmune pulmonary alveolar proteinosis
  • Pharmaceuticals

Savara Molgramostim FDA Decision Delayed: No New Date for First aPAP Drug

Megan Wood20 hours ago010 mins

The FDA will miss the 22 November goal date for Savara’s inhaled molgramostim in autoimmune PAP and has set no new date. What happened, the regulatory history and what analysts expect.

Read More
Xanamem Alzheimer's trial infographic: XanaMIA CDR-SB result, 247 patients, over-75 subgroup
  • Pharmaceuticals

Xanamem Alzheimer’s Trial Misses Main Goal, Actinogen Shares Plunge Over 80%

Megan Wood2 days ago010 mins

Actinogen’s oral Xanamem missed its CDR-SB primary endpoint in the 247-patient XanaMIA Alzheimer’s trial. We explain the over-75 subgroup signal, the share collapse and what comes next.

Read More
AI drug discovery timelines infographic with Novartis, Novo Nordisk and market data
  • Industry Insights

AI Drug Discovery Timelines: Big Pharma Says Early Research Now Runs Up to Twice as Fast

Megan Wood2 days ago011 mins

Novartis, Novo, Sanofi, BMS and others say AI has cut early drug discovery time by up to half. The numbers, the frontier AI rivalry and what has not changed.

Read More
UnitedHealth star ratings lawsuit infographic showing 45 contracts and 26 disputed measures
  • Industry Insights

UnitedHealth Star Ratings Lawsuit: Insurer Sues CMS Over 45 Medicare Advantage Contracts

Megan Wood2 days ago09 mins

UnitedHealth sues CMS over 2027 Medicare Advantage star ratings for 45 contracts, claiming up to 1.5 stars were lost. What is at stake and what comes next.

Read More
  • 1
  • 2
  • 3
  • …
  • 64

Categories

  • Healthcare IT (26)
  • Industry Insights (370)
  • Lifestyle and Wellness (24)
  • Medical Devices (45)
  • Pharmaceuticals (116)
  • Uncategorized (1)

Recent Posts

  • Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out
  • Novo Nordisk Layoffs: 215 More Jobs Cut at US Headquarters in Sales Overhaul
  • MAHA ELEVATE Model: CMS Awards $47M to 15 Groups to Test Lifestyle Medicine in Medicare
  • Rasonque EU Approval: Daraxonrasib Becomes Europe’s First RAS Pill for Pancreatic Cancer
  • Barzolvolimab Atopic Dermatitis Trial Fails: Celldex Drops Eczema to Focus on Hives

You May Have Missed

Spine Surgery Market Revenue, Trends, and Strategic Insights by 2032
  • Industry Insights

Spine Surgery Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 6 months ago
Pharmaceutical Market
  • Industry Insights

Pharmaceutical Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 9 months ago
Rasonque EU approval infographic showing daraxonrasib survival of 13.2 months versus 6.7 months on chemotherapy
  • Pharmaceuticals

Rasonque EU Approval: Daraxonrasib Becomes Europe’s First RAS Pill for Pancreatic Cancer

Megan Wood 18 hours ago
Graphic: vaccine research ethics shown as a balance scale in purple with gold pans
  • Industry Insights

Vaccine Research Ethics: Lessons From Guinea-Bissau Trial

Megan Wood 4 weeks ago4 weeks ago
CagriSema weight loss infographic showing 25.4% loss in early responders in REDEFINE 1
  • Pharmaceuticals

CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis

Megan Wood 7 days ago7 days ago
Vertex Q3 2026 results graphic on Crinetics deal cash and guidance
  • Pharmaceuticals

Vertex Q3 2026 Results: Revenue Rises 12% as Crinetics Deal Reshapes Cash, Margins and Guidance

Megan Wood 3 weeks ago3 weeks ago
Graphic: Gilead cancer drug pipeline deal with Vir, showing $90 million upfront and $1.74 billion in milestones
  • Pharmaceuticals

Gilead Cancer Drug Pipeline Gets Bold Bet With Vir

Megan Wood 1 month ago1 month ago
Benign Prostatic Hyperplasia Therapeutics Market Revenue, Trends, and Strategic Insights by 2032
  • Industry Insights

Benign Prostatic Hyperplasia Therapeutics Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 7 months ago
Digital Newspaper - Multipurpose News WordPress Theme 2026. Powered By BlazeThemes.